Tvardi Therapeutics is trading at $0.85, up 6.48%, amid supportive broader-market and biotech-sector strength. - No clear company-specific announcement explaining the November 4 move surfaced in the search; coverage mainly referenced prior analyst ratings and short-interest information. - Major U.S. indexes were sharply higher, while XBI gained 2.13%. - The move exceeded XBI’s gain, so market and sector conditions are plausible contributors, not a confirmed direct cause.